UPMC Hillman receives $11M SPORE in head and neck cancer

Kathryn Schmitz, José Zevallos named interim director, interim deputy director at UPMC Hillman

Kathryn SchmitzJosé ZevallosUPMC Hillman Cancer Center and the University of Pittsburgh announced that Kathryn Schmitz was appointed interim director of UPMC Hillman. José P. Zevallos was appointed as interim deputy director of UPMC Hillman.

January 31, 2025

Vol.51 No.04

In Brief

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Washington University researchers at Siteman Cancer Center received a $10.8 million grant throughNCI’s Specialized Programs of Research Excellence. Led by principal investigator Daniel C. Link, the five-year grant is a renewal of a previous SPORE grant in leukemia.

January 17, 2025

Vol.51 No.02

In Brief

Report shows UPMC Hillman’s nearly $4B economic impact in Pennsylvania

A recent report showed that UPMC Hillman Cancer Center generated $3.98 billion in total economic impact in Pennsylvania through its clinical, research, and educational missions in 2023.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

In Brief

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

October 18, 2024

Vol.50 No.39

By Jacquelyn Cobb

UPMC Hillman receives $11M SPORE in head and neck cancer

YOU MAY BE INTERESTED IN

Kathryn Schmitz, José Zevallos named interim director, interim deputy director at UPMC Hillman

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Report shows UPMC Hillman’s nearly $4B economic impact in Pennsylvania

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Renew today!

Subscriber content

Never miss an issue!

Login